Edition:
United States

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

3.43USD
20 Jul 2018
Change (% chg)

$-0.05 (-1.44%)
Prev Close
$3.48
Open
$3.45
Day's High
$3.46
Day's Low
$3.13
Volume
1,542,450
Avg. Vol
1,397,291
52-wk High
$6.68
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Geron Corporation Reports Q4 Loss Per Share $0.05
Friday, 16 Mar 2018 04:10pm EDT 

March 16 (Reuters) - Geron Corp ::ORATION REPORTS FOURTH QUARTER AND ANNUAL 2017 FINANCIAL RESULTS AND RECENT EVENTS.Q4 LOSS PER SHARE $0.05.Q4 EARNINGS PER SHARE VIEW $-0.05 -- THOMSON REUTERS I/B/E/S.EXPECTS PROTOCOL-SPECIFIED PRIMARY ANALYSIS FOR IMBARK TO BEGIN BY END OF Q2 OF 2018.  Full Article

Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019
Monday, 8 Jan 2018 07:57am EST 

Jan 8 (Reuters) - Geron Corp ::GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​.  Full Article

Geron says first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes
Monday, 20 Nov 2017 07:30am EST 

Nov 20 (Reuters) - Geron Corp ::Geron announces first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes.  Full Article

Geron Corp Q3 loss per share $0.04
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Geron Corp ::Geron Corporation reports third quarter 2017 financial results.Q3 loss per share $0.04.Q3 revenue $163,000.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Q3 revenue view $264,000 -- Thomson Reuters I/B/E/S.  Full Article

Geron announces fast track designation grant for imetelstat
Tuesday, 31 Oct 2017 07:30am EDT 

Oct 31 (Reuters) - Geron Corp :Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes.Geron Corp - FDA grants fast track designation for potential treatment of adult patients with transfusion-dependent anemia​.Geron- J‍anssen sponsored application for fast track designation using preliminary data from clinical trial being conducted by Janssen in lower risk MDS​.  Full Article

Geron Q2 loss per share $0.04
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Geron Corp :Geron Corporation reports second quarter 2017 financial results.Q2 loss per share $0.04.Q2 revenue $174,000.Q2 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Q2 revenue view $255,000 -- Thomson Reuters I/B/E/S.  Full Article

Geron Q1 loss per share $0.05
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Geron Corp :Geron Corporation reports first quarter 2017 financial results and recent events.Q1 loss per share $0.05.Q1 revenue $537,000.Q1 revenue view $181,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.  Full Article

Geron Corp and Janssen Research & Development LLC has completed second internal data reviews of Imerge and Imbark
Monday, 10 Apr 2017 07:30am EDT 

Geron Corp : Geron Corp - Janssen Research & Development, LLC has completed second internal data reviews of Imerge and Imbark . Geron Corp - For imerge, benefit/risk profile of Imetelstat in treated patients supports continued development in lower risk myelodysplastic syndromes . Geron-For Imbark, current results suggest clinical benefit, potential os benefit associated with Imetelstat treatment in relapsed or refractory myelofibrosis . Geron Corp - For Imerge, a data package and proposed trial design refinements are planned to be provided to FDA . Geron Corp - For Imbark, trial will continue unchanged to evaluate maturing efficacy and safety data, including an assessment of overall survival .Geron Corp - If part 2 of imerge is initiated, Geron expects this phase 3 stage of Imerge to be opened for patient enrollment in Q4 of 2017.  Full Article

Geron Corp says 2 parties to securities class action executed a stipulation and agreement of settlement to settle securities class action
Friday, 3 Mar 2017 07:45am EST 

Geron Corp : Geron corp says on March 2 parties to securities class action executed a stipulation and agreement of settlement to settle securities class action . Geron Corp says settlement does not constitute any admission of fault or wrongdoing by company or any of individual defendants . Geron Corp says expects $6.0 million of settlement amount to be paid by co's insurance providers and remaining $250,000 to be paid by co - SEC filing .Geron says in exchange for dismissal with prejudice of all claims against all defendants in lawsuit, co to settle securities class action for $6.25 million in cash.  Full Article

Geron qtrly loss per share $0.05
Wednesday, 1 Mar 2017 04:05pm EST 

Geron Corp : Geron Corporation reports fourth quarter and annual 2016 financial results .Qtrly loss per share $0.05.  Full Article

BRIEF-Geron Entered Into Market Issuance Agreement With B. Riley FBR

* GERON - ENTERED AT THE MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY FBR TO ISSUE AND SELL ITS COMMON STOCK WITH OFFERING PRICE OF UP TO $100 MILLION Source http://bit.ly/2Is6vuy Further company coverage: